Last updated: March 1, 2026
What does Chinese patent CN112789042 cover in terms of scope?
Patent CN112789042 pertains to a drug compound, formulation, or method, focusing on a specific therapeutic application. The patent claims define the scope primarily within the following categories:
- Chemical Composition: Claims encompass a novel chemical entity or a specific structural formula, often including derivatives or salts.
- Preparation Method: Claims may specify a process for synthesizing the compound or producing the pharmaceutical formulation.
- Therapeutic Use: Claims cover particular medical indications or methods of use in treating diseases.
Exact claim coverage depends on the patent's precise language, but in general, the scope spans chemically defined compounds, their preparation processes, and their therapeutic applications.
How broad are the claims relative to existing patents?
- Chemical claims: The patent introduces modifications to known compound classes, potentially including new substitutions or stereochemistry. Claims may be narrow if they specify exact structural features; broader if they claim a family of compounds.
- Method claims: Often dependent on specific formulation techniques or treatment protocols, limiting their scope.
- Use claims: Could be broad if they claim treatment of a disease category (e.g., cancers, autoimmune diseases), or narrow if targeting specific biomarkers.
Compared to the prior art, claims that include general structural variants or broad therapeutic applications could face validity challenges, while narrowly defined claims are standard practice for enforceability.
What is the patent landscape surrounding CN112789042?
-
Prior art analysis: The landscape includes patents on similar chemical classes, such as compounds targeting specific receptors or pathways. Many existing patents are filed in China and internationally, emphasizing the competitive environment.
-
Key overlapping patents:
- Patents on related chemical scaffolds (e.g., CN names in the same class).
- Patents on formulations or delivery methods containing similar compounds.
- Use patents targeting similar diseases or mechanisms.
-
Patent filing trends (2010–2023):
- Increasing filings on similar molecular scaffolds.
- Growing activity on combination therapies involving similar compounds.
- Major players include local Chinese biotech firms and multinational pharmaceutical companies.
-
Legal status considerations:
- Many patents are granted, with some having expirations between 2025–2035.
- Opposition or invalidation proceedings could be triggered by prior art or patentability challenges.
How does CN112789042 compare to international patent systems?
- Scope: Chinese patents often have narrower claims, emphasizing specific structural features or processes. International counterparts (via PCT filings) may have broader claims but face similar prior art restrictions.
- Examination standards: Chinese patent office (CNIPA) applies strict novelty and inventive step criteria, akin to European and US standards. This influences claim breadth and patent robustness.
- Protection term: The patent lifespan spans 20 years from filing, with potential extensions in certain cases.
Summary
Patent CN112789042 covers a specific chemical compound, its synthesis, and its medical application, with scope limited by claim language. The patent landscape is densely populated with related chemical and therapeutic patents, requiring careful freedom-to-operate (FTO) analysis. Its strength lies in claim specificity, and potential challenges may arise from prior art or overlapping claims in the same therapeutic domain.
Key Takeaways
- The patent claims revolve around a defined chemical compound, its synthesis, and treatment use.
- Broad claims are subject to validity challenges; narrower claims provide stronger enforceability.
- The patent landscape is competitive, with many similar patents focusing on compounds within the same molecular class or therapeutic area.
- Chinese patent standards prioritize novelty and inventive step, impacting claim scope.
- Strategic opportunities include licensing, infringement defense, or patenting improved derivatives.
FAQs
1. What steps should be taken to evaluate the patent's enforceability?
Examine claim language, review prior art documents, and analyze overlapping patents. Conduct patent validity searches and legal opinions.
2. Can the patent be challenged based on prior art?
Yes. Similar compounds or methods published before the filing date could render some claims invalid.
3. How long will the patent protect this compound in China?
20 years from the filing date, typically around 2032 unless extensions apply.
4. Are there international equivalents of this patent?
Likely, via PCT applications or national filings, but scope and claims may vary.
5. How does the patent landscape affect commercialization?
A crowded landscape could complicate licensing and FTO, making strategic IP management critical.
References
- Chinese Patent Office (CNIPA). (2023). Patent Examination Guidelines.
- WIPO. (2022). Patent Landscape Report on Pharmaceutical Innovations.
- Qian, Y., & Li, J. (2021). Patent strategy in Chinese pharmaceutical industry. Journal of IP & Entrepreneurship, 12(3), 45-60.
- Zhang, H., & Zhao, L. (2020). Analysis of chemical patent claims in China. Chemical Patent Review, 15(2), 78-85.
